Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Anatomic Stage II Breast Cancer AJCC v8 clinical trials
40 of 74 indexed Anatomic Stage II Breast Cancer AJCC v8 trials are currently recruiting.
74 US clinical trials · 40 currently recruiting
Anatomic Stage II Breast Cancer AJCC v8 is the subject of 74 registered US clinical trials on ClinicalTrials.gov, 40 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 12 of these trials.
The research picture
Anatomic Stage II Breast Cancer AJCC v8 has 74 registered US clinical trials, 40 of them open to new participants right now, about 54% of the total.
- 40
- recruiting participants now
- 54%
- of trials open to enrollment
- 9
- in Phase 3–4 (later-stage)
- 12
- top sponsor: M.D. Anderson Cancer Center
Active & Recent Trials
74 total, page 1 of 2
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
National Cancer Institute (NCI)
NCT06058377
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
SWOG Cancer Research Network
NCT05929768
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Alliance for Clinical Trials in Oncology
NCT06876714
Breast Cancer Survivorship Biorepository
University of Southern California
NCT05786664
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Alliance for Clinical Trials in Oncology
NCT05812807
Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial
Fred Hutchinson Cancer Center
NCT05930483
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
University of Southern California
NCT07259304
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
Mayo Clinic
NCT04517838
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
City of Hope Medical Center
NCT06763328
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
City of Hope Medical Center
NCT06042569
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
Jonsson Comprehensive Cancer Center
NCT06113016
Breast Cancer, Reasoning, and Activity Intervention
Mayo Clinic
NCT04816006
Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
Emory University
NCT06534125
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
Mayo Clinic
NCT06635980
Integrative Approaches for Cancer Survivorship (IACS3)
University of California, San Francisco
NCT06633926
The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients
Ohio State University Comprehensive Cancer Center
NCT07341503
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
Jonsson Comprehensive Cancer Center
NCT05595499
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
City of Hope Medical Center
NCT06954831
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
University of Michigan Rogel Cancer Center
NCT07158021
Evaluating the Association Between Changes in the Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer
Mayo Clinic
NCT05417867
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
University of Washington
NCT05183828
Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT06582615
Neoadjuvant Breast Cancer Time Restricted Eating
Thomas Jefferson University
NCT05327608
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Vandana Abramson
NCT07016399
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT05417308
A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment
University of Alabama at Birmingham
NCT05243056
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT05677802
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
Emory University
NCT05464810
5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
Mayo Clinic
NCT07044310
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
City of Hope Medical Center
NCT06538389
Geriatric Care Survivorship Intervention for Improving the Overall Health of Older Adults With Stage I-III Breast Cancer Who Have Completed Curative Treatment
M.D. Anderson Cancer Center
NCT05928325
A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy
Emory University
NCT05488145
Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast Cancer Survivors
University of Alabama at Birmingham
NCT05452681
Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer
Emory University
NCT05368428
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
University of Washington
NCT04329065
Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
Mayo Clinic
NCT06401889
An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial
Mayo Clinic
NCT06999798
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Emory University
NCT06324240
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
NCT05319873
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
M.D. Anderson Cancer Center
NCT02918474
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
ECOG-ACRIN Cancer Research Group
NCT04266249
Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer
M.D. Anderson Cancer Center
NCT04678414
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
SWOG Cancer Research Network
NCT03939481
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Alliance for Clinical Trials in Oncology
NCT04379570
Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer
M.D. Anderson Cancer Center
NCT01334021
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Alliance for Clinical Trials in Oncology
NCT04457596
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
SWOG Cancer Research Network
NCT05568472
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
Alliance for Clinical Trials in Oncology
NCT04549571
Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors
Ohio State University Comprehensive Cancer Center
NCT04906200
A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer
Thomas Jefferson University
NCT04086875
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 18 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Anatomic Stage II Breast Cancer AJCC v8 Trial Landscape
74 indexed Anatomic Stage II Breast Cancer AJCC v8 studies · 40 recruiting (54%).
Phase mix: 9 late (III/IV) vs 26 early (I/II).
Top sponsor: M.D. Anderson Cancer Center (12 trials), 9 others listed. 50 shown below, recruiting first.
How to read this condition's trial landscape
That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Anatomic Stage II Breast Cancer AJCC v8?
PlainTrial tracks 74 US clinical trials for Anatomic Stage II Breast Cancer AJCC v8, of which 40 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Anatomic Stage II Breast Cancer AJCC v8?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.